DEA's fourth temporary extension of telemedicine prescribing flexibilities expires on December 31, 2026. Until that date, DEA-registered practitioners can prescribe Schedule II through V controlled substances through qualifying telemedicine encounters without first conducting an in-person medical evaluation, provided all applicable conditions are met. For telehealth businesses affected by the Ryan Haight Act, the deadline creates an important planning question about how controlled-medication programs will operate in 2027.
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before prescribers can prescribe controlled substances online, subject to specific exceptions. Temporary federal flexibilities have allowed qualifying remote prescribing without that initial examination, but operators of. Still, operators, treatment, and men's health programs need to distinguish today's permissions from the rules that may apply after the extension expires.
What the 2008 Law Requires
The Ryan Haight Act was enacted to address improper prescribing and distribution of controlled substances over the internet. Its central requirement is that practitioners generally must perform at least one in-person medical evaluation before issuing a controlled-substance prescription through the internet, unless a statutory exception applies.
One important exception involves the legally defined practice of telemedicine. The Act recognizes specific circumstances where remote prescribing may be authorized without the usual prior in-person examination.
Once a practitioner has conducted a qualifying in-person medical evaluation of a patient, the Act generally does not require that practitioner to repeat the examination solely to continue prescribing remotely. The prescription must still serve a legitimate medical purpose and satisfy other applicable federal and state requirements.
The temporary exceptions introduced during the COVID-19 emergency broadened remote-prescribing options. Under the current extension, qualifying practitioners can prescribe Schedule II through V medications through audio-video telemedicine, with certain additional audio-only permissions for medications used to treat opioid use disorder.
HHS's guidance on prescribing controlled substances via telehealth confirms that these flexibilities extend through December 31, 2026.
This distinction matters for telehealth founders because a digital intake questionnaire alone does not establish that a controlled-substance prescription qualifies for a telemedicine exception. The permitted encounter method, prescriber's authority, medication, and applicable rules all need to be considered.
How We Got Here
The current deadline follows several years of temporary extensions and efforts to establish permanent telemedicine prescribing rules.
- 2008: Congress enacts the Ryan Haight Online Pharmacy Consumer Protection Act, establishing restrictions on internet prescribing of controlled substances and exceptions for qualifying telemedicine.
- 2020: During the COVID-19 public health emergency, DEA introduces temporary exceptions allowing qualifying practitioners to prescribe controlled medications without first conducting an in-person medical evaluation.
- 2023 to 2025: DEA and HHS repeatedly extend the temporary flexibilities while considering how to create a lasting framework for remote prescribing.
- January 17, 2025: Federal agencies publish two final rules concerning buprenorphine treatment through telemedicine and continuity of care for certain Department of Veterans Affairs patients. DEA also proposes a broader special-registration framework for telemedicine prescribing.
- December 31, 2025: The fourth temporary extension is published, covering January 1 through December 31, 2026. The two narrower final rules also take effect on December 31, 2025, following earlier delays.
- August 25, 2026: DEA submits its special-registration rule for White House regulatory review, according to the federal regulatory review record. The submission indicates progress in the rulemaking process but does not establish the final requirements or publication date.
- December 31, 2026: The fourth temporary extension is scheduled to expire unless federal agencies take further action.
The repeated extensions allowed telehealth prescribers and patients to continue using telehealth care arrangements. However, temporary flexibility is different from permanent authorization, especially for organizations whose business models depend on patients beginning treatment entirely online.
As of October 2026, the special-registration framework has not been published as a final rule. Its potential requirements should therefore be treated as unresolved rather than incorporated into operating procedures as though already effective.
Which Telehealth Programs It Touches
The Act's relevance depends primarily on whether a program involves controlled substances. Not every prescription-only medication is federally controlled, and programs serving similar patient populations can face different prescribing requirements.
The DEA's drug scheduling guidance distinguishes controlled medications by schedule. The following table shows how that classification affects common telehealth offerings.
| Telehealth Program | Example Medication | DEA Schedule | Covered by the Act? |
|---|
| ADHD treatment | Adderall, Ritalin | II | Yes |
| Testosterone therapy | Testosterone | III | Yes |
| Opioid use disorder | Buprenorphine | III | Yes, with a separate permanent telemedicine pathway |
| Sleep and anxiety care | Ambien, Xanax | IV | Yes |
| Weight management with phentermine | Phentermine | IV | Yes |
| GLP-1 weight management | Semaglutide, tirzepatide | Not federally controlled | No |
For a telehealth brand offering testosterone therapy, the Schedule III classification means that prescribing workflows must account for federal controlled-substance restrictions. A synchronous encounter may be necessary under the applicable telemedicine pathway, alongside appropriate clinical evaluation and prescribing safeguards.
Weight management illustrates a different distinction. Phentermine is a Schedule IV controlled substance, whereas semaglutide and tirzepatide are not federally scheduled controlled substances. Consequently, a business offering weight-loss telehealth should not assume that every medication used in the same se category follows identical teleprescribing rules.
Brands focused on GLP-1 programs may fall outside the Ryan Haight Act for those particular medications, but remain subject to relevant prescribing, licensing, privacy, and other healthcare requirements.
Buprenorphine deserves separate treatment because the January 2025 final rule established an additional telemedicine pathway for qualifying opioid use disorder treatment. That pathway includes safeguards, including limits on prescribing without an in-person evaluation and conditions for subsequent prescriptions. It should not be interpreted as unlimited remote prescribing without further qualification.
Federal prescribing permission also does not eliminate state requirements. Applicable PDMP checks, state prescribing restrictions, professional licensing, and recordkeeping obligations may impose further conditions on controlled-medication programs.
The operational question is therefore broader than whether the medication is on a federal schedule. A telehealth business needs to understand which rules govern its specific medication, encounter method, clinician, patient location, and prescribing process.
Three Ways January 1, 2027 Could Look
The current extension establishes what is permitted through December 31, 2026, but it does not determine what federal rules will apply the following day.
Three regulatory outcomes remain relevant for telehealth operators. These are planning scenarios, not predictions.
A Final Special Registration Rule
DEA could publish a final special-registration rule that establishes a long-term framework allowing qualifying practitioners to prescribe controlled substances through telemedicine without an initial in-person examination.
The January 2025 proposal contemplated registration categories and additional prescribing, recordkeeping, and oversight requirements. However, the final text may differ from the proposal, and its precise requirements, eligibility criteria, implementation dates, and operational consequences cannot be assumed before publication.
For a telehealth company, this scenario could affect which clinicians may prescribe remotely, what registration arrangements are necessary, and how controlled-medication workflows are documented.
Until the final rule is available, building an entire service model around assumed registration permissions would create unnecessary uncertainty.
Another Temporary Extension
DEA and HHS could issue another temporary extension before the current one expires.
Federal agencies have already extended these flexibilities four times, primarily to preserve continuity of treatment while longer-term policy is developed. A further extension could give providers more time to meet permanent requirements. Still, no fifth extension: operators should not assume one; the main benefit of this scenario would be additional time under whatever conditions the agencies establish. It would not eliminate the need to monitor the eventual permanent framework or comply with existing state prescribing requirements.
The Flexibilities Lapse
If no replacement rule or further extension takes effect, the broad temporary permission to prescribe Schedule II through V controlled substances without a prior in-person evaluation would expire at the end of December 31, 2026.
The Ryan Haight Act's general in-person medical evaluation requirement would again become central for remote prescribing, except where another existing statutory or regulatory pathway authorizes it.
Those pathways include the permanent buprenorphine telemedicine rule for qualifying opioid use disorder treatment and the narrower Veterans Affairs continuity-of-care rule. Both operate under their own conditions and should not be treated as blanket exceptions for every telehealth prescriber.
A lapse could require some programs to arrange qualifying in-person evaluations, change their clinical delivery model, or stop offering certain remote-prescribing pathways until an authorized alternative is available. The impact would depend on each program's circumstances, patient relationships, and applicable laws.
Running Live and Async Visits on Bask
Each of the three outcomes comes down to the same operational question: which programs need a live visit and which can stay asynchronous. Bask supports both synchronous and asynchronous care, with video calls, chat, and secure portals alongside questionnaire-based visits. Brands can build customizable treatment pathways, so a testosterone program and a GLP-1 program can run different visit flows under one brand.
Clinicians can come from the integrated doctor groups included on every Bask plan, or Currentd's own network on Enterprise. Which exempt qualifying controlled-substance prescriptions from the controlled-medication program legally requires, and prescriptions of controlled substances, is still for the brand and its clinicians to decide.
FAQs
Is the Ryan Haight Act Still in Effect?
Yes. The Ryan Haight Act remains federal law. The current temporary telemedicine flexibilities exempt qualifying controlled-substance prescriptions from the usual prior in-person examination requirement through December 31, 2026.
The extension does not repeal the Act, and other federal and state prescribing requirements continue to apply.
Will Telehealth Be Allowed for Controlled Substances in 2027?
Certain telemedicine prescribing pathways already have permanent regulatory provisions, including qualifying buprenorphine treatment and specific Veterans Affairs circumstances. For broader remote access without an initial in-person examination, the answer depends on whether DEA and HHS finalize additional rules or extend the temporary flexibilities.
As of October 2026, the outcome for January 1, 2027, has not been established by a published replacement final rule.
Does the Ryan Haight Act Apply to GLP-1 Prescriptions?
Not to semaglutide or tirzepatide based on controlled-substance scheduling, because neither is federally classified as a controlled substance.
Phentermine is different. It is Schedule IV and therefore falls within the federal framework governing controlled-substance prescriptions, including the Ryan Haight Act's applicable telemedicine provisions.
Do States Have Their Own Telehealth Prescribing Rules?
Yes. State law may govern professional licensure, clinician-patient relationships, prescribing requirements, PDMP reviews, and other aspects of remote care.
A federal exception does not automatically authorize an encounter that violates state requirements. Telehealth operators must also evaluate applicable state telehealth rules wherever their patients receive care.
References
- Federal Register. (2025). Fourth temporary extension of COVID-19 telemedicine flexibilities for prescription of controlled medications. https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
- U.S. Department of Health and Human Services. (2026). Prescribing controlled substances via telehealth. https://telehealth.hhs.gov/providers/telehealth-policy/prescribing-controlled-substances-via-telehealth
- Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
